UPDATE 1-Lynparza stalls pancreatic cancer in patients with BRCA mutations -study
June 02, 2019 at 13:10 PM EDT
AstraZeneca and Merck & Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.
